Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.1.21 (
thymidine kinase
)
7,561
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The density decrease of vaccinia virus-infected L-M cells observed in a Ficoll density gradient by 2 h postinfection was found to be dependent on RNA synthesis and protein synthesis but independent of DNA synthesis. Using low multiplicities of infection, the required RNA and protein species appeared to be synthesized before parental viral DNA became sensitive to DNase, i.e., while the bulk of input virus was still at the core stage of uncoating. To date only
thymidine kinase
and a vaccinia virus-specific
cell surface antigen
(as well as the putative uncoating protein) have been shown to be "early early" proteins, i.e., synthesized while parental viral DNA is still enclosed within the core. Both heat- and UV-inactivated virus failed to cause the cell density decrease. The need for a functioning viral genome implies that the required early early RNA and protein species are virus specific and not cell specific. Thus the protein leading to the density decrease of L-M cells, induced very early after infection with vaccinia virus, represents one of the first bits of viral genetic information expressed after infection. Since antibody-neutralized virus is still capable of causing the phenomenon of cell density decrease, the basis of neutralization of vaccinia virus by specific antibody must be other than by inhibiting early early transcription and/or translation.
...
PMID:Evidence for an "early early" vaccinia virus-induced protein which causes a density change of infected L-M cells. 123 18
The human 4F2
cell surface antigen
is a 120-kilodalton (kDa) disulfide-linked heterodimer which is composed of an 80- to 90-kDa glycosylated heavy chain (4F2HC) and a 35- to 40-kDa nonglycosylated light chain (4F2LC). 4F2 belongs to a family of inducible cell surface molecules which are involved in T-lymphocyte activation and growth. To better understand the molecular mechanism(s) that controls 4F2HC gene expression in both resting and activated T cells, a 4F2HC human genomic clone was isolated and structurally characterized. The 4F2HC gene spans 8 kilobases of chromosome 11 and is composed of nine exons. The 5' upstream region of the gene displays several properties which are characteristic of housekeeping genes. It is G+C rich and hypomethylated in peripheral blood lymphocyte DNA and contains multiple binding sites for the Sp1 transcription factor while lacking TATA or CCAAT sequences. This region of the gene also displays sequence homologies with several other inducible T-cell genes, including the interleukin-2, interleukin-2 receptor alpha chain, dihydrofolate reductase,
thymidine kinase
, and transferrin receptor genes. A 255-base-pair fragment of the 4F2HC gene which contains 154 base pairs of the 5' flanking sequence was able to efficiently promote expression of the bacterial chloramphenicol acetyltransferase gene in human Jurkat T cells, indicating that it contains promoter or enhancer (or both) sequences. Analyses of chromatin structure in resting and lectin-activated T cells revealed the presence of stable DNase I-hypersensitive sites within both the 5' flanking and intron 1 regions of the 4F2HC gene. Although the 4F2HC gene displayed many of the structural features characteristic of a constitutively expressed gene, lectin-mediated activation of resting peripheral blood T lymphocytes resulted in a dramatic increase in steady-state levels of 4F2HC mRNA.
...
PMID:Isolation and structural characterization of the human 4F2 heavy-chain gene, an inducible gene involved in T-lymphocyte activation. 326 70
Donor lymphocyte infusions (DLI) following allogeneic stem cell transplantation are known to mediate graft-versus-leukemia effect (GVL). A major side effect of these immunotherapies is the development of graft-versus-host diseases (GVHD). One promising approach to prevent GVHD is to genetically modify donor T cells with a suicide mechanism that can be induced in the case of GVHD. Here we report on a retroviral vector containing the death effector domain (DED) of the human Fas-associated protein with death domain (FADD). The DED was fused to two copies of an FKBP506-binding protein and a truncated version of the human low-affinity receptor for nerve growth factor (LNGFR). Activation of the death signal pathway can be triggered upon the addition of chemical inducers of dimerization. This construct was functionally compared to an optimized HSV-TK vector in which a hypersensitive mutant of the herpes simplex virus
thymidine kinase
gene (TK39) was fused to a cytoplasmic truncated version of the
cell surface antigen
CD34. A direct comparison between both vectors in primary T lymphocytes showed that the number of T cells transduced with vectors containing the DED was significantly reduced within 24 h of drug administration whereas ganciclovir treatment of TK39-transduced T cells showed a delay in cell death of approximately 3-4 days. Our results indicate that constructs containing the DED may prove to be the most efficient mechanism to quickly eliminate alloreactive T cells.
...
PMID:Kinetics of cell death in T lymphocytes genetically modified with two novel suicide fusion genes. 1283 28